GlassScriptPhysician profile
Susann Mischke
NPI 1366067449
$6,594.22
in general payments reported to CMS, 2019-2025
26 companies · $977 in 2025
The $977 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $670 · 2022: $2,855 · 2023: $1,012 · 2024: $1,080 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.18 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,750.69 | 2021-2025 | Micra, Symplicity G3, Venaseal |
| Edwards Lifesciences Corporation | $1,191.85 | 2021-2025 | Sapien 3 Ultra Resilia, Pascal |
| Merck Sharp & Dohme LLC | $396.49 | 2023-2025 | Verquvo, Winrevair |
| Boston Scientific Corporation | $335.68 | 2022-2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $299.96 | 2022-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.20 | 2023-2025 | Jardiance |
| Heartflow, INC. | $219.54 | 2023-2024 | Ffrct |
| Novartis Pharmaceuticals Corporation | $199.63 | 2023-2025 | |
| Amgen INC. | $134.84 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $115.60 | 2023-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.94 | 2022-2024 | Lifevest |
| Esperion Therapeutics, INC. | $99.68 | 2023-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $88.52 | 2022-2025 | Camzyos, Eliquis |
| United Therapeutics Corporation | $79.26 | 2023-2025 | Tyvaso, Orenitram, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $53.56 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $38.23 | 2024 | |
| Janssen Pharmaceuticals, INC | $37.48 | 2024 | Xarelto |
| Pfizer INC. | $24.56 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $23.76 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $22.24 | 2025 | |
| Lilly USA, LLC | $19.81 | 2025 | Zepbound |
| Abiomed | $19.80 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.17 | 2024 | |
| Bridgebio Pharma, INC. | $16.68 | 2025 | Attruby |
| Irhythm Technologies, INC. | $15.70 | 2022 | |
| Novo Nordisk INC | $14.35 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susann Mischke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.